Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.

Weitere Produkte vom selben Autor

Geschäftsmodelle entwickeln Gassmann, Oliver, Frankenberger, Karolin, Choudury, Michaela

44,99 €*
Der St. Galler Business Model Navigator Gassmann, Oliver, Frankenberger, Karolin, Choudury, Michaela

49,99 €*
Digitale Transformation gestalten Gassmann, Oliver, Sutter, Oliver

52,70 €*
Führung und Organisation pharmazeutischer Innovation Gassmann, Oliver, Schuhmacher, Alexander, Zedtwitz, Max Von, Reepmeyer, Gerrit

44,99 €*